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a  b  s  t  r  a  c  t
With  the  aim  to enlarge  the set  of  available  ﬂavoprotein  monooxygenases,  we  have  cloned  8 unexplored
genes  from  Rhodococcus  jostii  RHA1  that  were  predicted  to encode  class  B ﬂavoprotein  monooxygenases.
Each  monooxygenase  can  be  expressed  as soluble  protein  and  has  been  tested  for conversion  of  sulﬁdes
and ketones.  Not  only  enantioselective  sulfoxidations,  but  also  enantioselective  Baeyer–Villiger  oxida-
tions  could  be  performed  with  this  set of  monooxygenases.  Interestingly,  in  contrast  to known  class  B
ﬂavoprotein  monooxygenases,  all studied  biocatalysts  showed  no nicotinamide  coenzyme  preference.
This  feature  coincides  with  the fact  that  the respective  sequences  appear  to  form  a discrete  group  of




the  so-called  ﬂavin-containing  monooxygenases  (FMOs),  N-hydroxylating  monooxygenases  (NMOs)  and
Type  I Baeyer–Villiger  monooxygenases  (BVMOs).  Taken  together,  these  data  reveal  the existence  of
a new  subclass  of class  B  ﬂavoprotein  monooxygenases,  which  we  coined  as Type  II FMOs,  that  can
perform  Baeyer–Villiger  oxidations  and  accept  both  NADPH  and  NADH  as  coenzyme.  The  uncovered  bio-
catalytic  properties  of  the  studied  Type  II FMOs  make  this  newly  recognized  subclass  of  monooxygenases
of  potential  interest  for  biocatalytic  applications.. Introduction
Flavoprotein monooxygenases are attracting attention as selec-
ive and oxidative biocatalysts that can be used for the production
f high-value chemical building blocks or pharmaceuticals [1].
hese biocatalysts efﬁciently catalyze chemo-, regio-, and/or enan-
ioselective oxygenations using dioxygen as mild oxidant while
sing NAD(P)H as reductant. Flavoprotein monooxygenases can be
ivided into 6 distinct classes, with each class containing sequence-
nd structure-related monooxygenases. Two of these classes (class
 and B) are especially appealing when considering biocatalysis.
hese two classes are typiﬁed by being single component enzymes
hat contain a tightly bound ﬂavin cofactor, while the other
onooxygenases rely on multiple protomers and often employ a
oosely bound ﬂavin cofactor. The class A of ﬂavoprotein monooxy-
enases seems to have evolved to catalyze aromatic hydroxylations,
s most of the characterized monooxygenases of this class rep-
esent hydroxylases, typically acting on a very restricted number
f substrates [2].  Class B ﬂavoprotein monooxygenases do not
Abbreviations: CE, cell extract; CCE, cleared cell extract; FMOs, ﬂavin-
ontaining monooxygenases; NMOs, N-hydroxylating monooxygenases; BVMOs,
aeyer–Villiger monooxygenases.
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catalyze hydroxylations but perform Baeyer–Villiger oxidations
and/or oxygenations of heteroatom-containing compounds. In fact,
three class B ﬂavoprotein monooxygenase subclasses have been
identiﬁed based on speciﬁc sequence motifs, which coincide with
a preference for speciﬁc oxygenation types for each subclass [3]:
1. Baeyer–Villiger monooxygenases (BVMOs) contain the
sequence motif (FxGxxxHxxxWP/D) and primarily catalyze
Baeyer–Villiger oxidations, while they are also able to oxy-
genate heteroatom-containing compounds (N, S, B or Se
containing compounds);
2. The so-called ﬂavin-containing monooxygenases (FMOs) con-
tain a slightly different sequence motif (FxGxxxHxxxYK/R), and
are specialized in oxidizing heteroatom-containing compounds
while they are inefﬁcient in catalyzing Baeyer–Villiger oxi-
dations. The FMOs have mainly been studied as xenobiotic
degrading enzymes that help the human body to dispose toxic
compounds [4,5]. The human proteome encompasses six FMO
isoforms [6],  which are able to activate or degrade many drugs.
Only very recently FMOs have been considered for their use as
biocatalysts, due to the identiﬁcation and production of a micro-
bial FMO  which, in contrast to the human homologs, can be easily
expressed as a soluble protein [7].
3. N-hydroxylating monooxygenases (NMOs) share sequence
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monooxygenases but lack a typifying sequence motif. Only a con-
served histidine can be identiﬁed in the region of the BVMO/FMO
sequence motif. So far only a few NMOs from bacteria and fungi
have been reported. They typically convert long-chain primary
amines by N-hydroxylation [8].
The overall sequence homology among all class B ﬂavo-
rotein monooxygenases reﬂects the fact that they are all
ingle-component FAD-containing monooxygenases composed of
wo dinucleotide binding domains (Rossman folds to bind both
AD and NADPH), that allow them to combine ﬂavin reduction and
onooxygenation in one polypeptide chain. They often prefer the
se of NADPH as electron donor, keeping the NADP+ tightly bound
hroughout the catalytic cycle [9,10].  From the three subclasses,
ainly the BVMOs have been extensively studied as biocatalysts.
To tap the natural diversity for the discovery of novel oxygenat-
ng enzymes Rhodococcus jostii RHA1 is a very promising candidate.
he proteome of this bacterium is predicted to contain an unusually
igh variety of oxidative enzymes [11,12]. Inspired by this obser-
ation, we and the Grogan group have recently cloned 22 putative
VMO-encoding genes, and succeeded in producing and exploring
he biocatalytic properties of these enzymes [13,14]. This research
as conﬁrmed that all these enzymes indeed act as BVMOs which
an be used for a large number of oxygenations. When screening
he predicted proteome of R. jostii RHA1 for monooxygenases, we
lso identiﬁed a relatively large number of other putative class B
onooxygenases that seem to be more closely related to NMOs
nd FMOs. While BVMOs are relatively rare enzymes that are only
ound in bacteria and fungi with an average distribution of only one
r two BVMO-encoding genes per microbial genome [15], FMOs
nd NMOs are even more scarce in microbes. FMOs are quite abun-
antly present in higher eukaryotes (e.g. the 6 isoforms in the
uman genome and often more than 10 in plant genomes [16]), but
hese FMOs are often difﬁcult to produce due to their membrane
ssociation.
In this paper, we report on the exploration of 8 novel class B
avoprotein monooxygenases obtained from a single microorgan-
sm, R. jostii RHA1, that share sequence homology with FMOs and
MOs. By optimizing expression vectors and expression conditions,
ll enzymes were obtained in soluble and holo form. A set of ketones
nd aromatic sulﬁdes was tested for all enzymes to explore their
iocatalytic potential. Also their coenzyme speciﬁcity and enan-
ioselective properties were analyzed.
. Experimental
.1. General materials and methods
Oligonucleotide primers were purchased from Sigma, dNTPs
nd In-FusionTM 2.0 CF Dry-Down PCR Cloning Kit from Clontech,
husion polymerase from Finnzymes. All other chemicals were
btained from Acros Organics, ABCR, Sigma–Aldrich, TCI Europe,
nd Roche Diagnostics GmbH. The nicotinamide coenzymes were
urchased from Codexis.
The NCBI server (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was
sed for DNA sequence retrieval and BLAST searches. The EBI
erver (http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used for
ultiple sequence alignment by CLUSTALW [19]. Treeview soft-
are (http://taxonomy.zoology.gla.ac.uk/rod/treeview.html) was
sed for visualization of the sequence relationships..2. Cloning and expression
Escherichia coli TOP10 from Invitrogen was used as a host
or DNA manipulations and protein expression. Two  expressionlysis B: Enzymatic 88 (2013) 20– 25 21
vectors have been used: (i) a modiﬁed pBAD vector (pBADN) in
which the NdeI site was  replaced by the original NcoI site [17], and
(ii) the recently engineered pBAD-based pCRE2 vector which har-
bors a codon-optimized gene encoding a thermostable mutant of
phosphite dehydrogenase (PTDH) with an N-terminal His-tag [18].
The target genes were ampliﬁed by PCR using genomic DNA of
R. jostii RHA1 as template and subsequently cloned into pBADN
using the In-Fusion PCR Cloning kit from Clontech, following the
recommendations of the manufacturer. Expression of all generated
expression constructs was  tested using 24-multiwell microtiter
plates in the sandwich cover system from Enzyscreen®. Cell cul-
tures of 2.5 mL  in LB medium supplemented with 50 g mL−1
ampicillin were grown at four different temperatures (17 ◦C for
48 h; 24 ◦C for 32 h; 30 ◦C and 37 ◦C for 16 h) with four differ-
ent arabinose concentrations (0.002%, 0.02%, 0.2%, and none) each,
with shaking at 200 rpm. Cell extracts (CEs) were obtained using
DNase/lysozyme in combination with freezing in liquid nitrogen
and thawing at 30 ◦C. CEs as well as cell cleared extracts (CCEs) were
analyzed by SDS-PAGE for (soluble) expression of the monooxyge-
nases. For the genes that did not yield expressed soluble protein
when cloned into pBADN, the in-house developed pCRE2 expres-
sion vector was used.
2.3. General procedure for the bioconversions employing the
novel FMOs
Conversions were performed essentially as described before
[14]. For GC analysis, 500 L incubations of 50 mM Tris/HCl pH 7.5,
10% glycerol, 1 mM  DTT, 1 mM EDTA, 10 M FAD, 5 mM substrate,
5% cosolvent (1,4-dioxane), 100 M NADPH, 3.1 M PTDH, 10 mM
phosphite and 5 M of the corresponding monooxygenase in CCE
form (total volume of 0.5 mL), were shaken in glass vials at 24 ◦C
for 24 h. For determining the exact concentration of each enzyme
in the respective extract, a recently developed method was  used
which relies on the decrease in absorbance at 450 nm upon NADPH-
mediated reduction of the ﬂavin cofactor [14]. Each conversion
was stopped by extracting with ethyl acetate (2 × 0.5 mL  contain-
ing 0.1% mesitylene as standard), dried with magnesium sulfate
and analyzed directly by GC to determine the degree of conversion
and the enantioselectivity. The details concerning the (chiral) GC
analysis can be found in the Supplemental information (Table S1).
For every tested reaction, control experiments in the absence of
enzyme resulted in no conversion.
3. Results
3.1. Identiﬁcation of putative FMO/NMO-encoding genes
By a PBLAST search of the proteome of R. jostii RHA1 [11],
not only 23 Type I BVMO-encoding genes could be found [14],
but also another 8 genes putatively encoding class B ﬂavoprotein
monooxygenases could be identiﬁed. All corresponding proteins
contain two typical Rossman fold motifs (GxGxxG), clearly dis-
tinguishing them from other ﬂavoprotein monooxygenase classes.
As for all class B ﬂavoprotein monooxygenases, one Rossman fold
motif is close to the N-terminus while the other is in the mid-
dle of the sequences. In our previous work [14], we proposed a
new conserved sequence motif typical for the Type I BVMO family:
[A/G]GxWxxxx[F/Y]P[G/M]xxxD located between the two  Rossman
fold motifs. This motif entails the conserved active site aspar-
tate and therefore appears a better ﬁngerprint for Type I BVMO
sequences. The motif is absent in all sequences used in this study
and conﬁrms that they do not represent classical BVMOs. The
sequences do also not contain the previously described BVMO-
typifying motif. In fact, most of them (all except for monooxygenase
22 A. Riebel et al. / Journal of Molecular Catalysis B: Enzymatic 88 (2013) 20– 25
Table 1
All identiﬁed class B monooxygenases with their sequence characteristics and expression performance in E. coli.






Length (aa) Soluble a
expression
FMO-A RHA1 ro00740 GxGxxG WxGxxxHxxxYR GxGxxG 375 ++b
FMO-B RHA1 ro03334 GxGxxG AxIxxxHxxxYR GxGxxG 418 ++
FMO-C RHA1 ro04494 GxGxxG PxIxxxHxxxYR GxSxxG 365 ++
FMO-D RHA1 ro05032 GxGxxG FxGxxxHxxxYS GxGxxA 369 ++b
FMO-E RHA1 ro00824 GxGxxG FxGxxxHxxxYD GxGxxA 580 ++
FMO-F RHA1 ro04244 GxGxxG FxGxxxHxxxHP GxNxxA 602 +++
FMO-G RHA1 ro05696 GxGxxG FxGxxxHxxxFV GxCxxG 595 +++




















Ia + Indicates a clear visible protein band using SDS-PAGE, while +++ indicates a g
b Indicates that the respective monooxygenase has been expressed using the pCR
) appear more closely related to FMOs as the FMO-typifying
equence motif can be recognized with only one or two  amino acid
ubstitutions (see Table 1). This is also reﬂected by the fact that most
f the sequences have been annotated in the sequence database
s putative ﬂavin-containing monooxygenases. When performing multiple sequence alignment, the clustering becomes apparent.
onooxygenase H is most related to known NMOs, while the other
roteins form another distinct group of sequence-related proteins
Fig. 1). It also shows that all studied sequences are quite distant
ig. 1. An unrooted phylogenetic tree of the studied monooxygenases and known class 
ycobacterium tuberculosis H37Rv (NP 218371.1); HAPMO, Pseudomonas ﬂuorescens ACB (
BAE93346.1); CHMO1, Acinetobacter calcoaceticus NCIMB 9871 (BAA86293.1); PAMO, Ther
p.  strain TY-5 (BAF43791.1); MEKMO, P. veronii MEK700 (ABI15711.1); CPMO, Comamo
or  numbering)], type I FMOs [Arabidopsis thaliana: FMO1Ara(Q9LMA1); FMO2Ara (Q9FKE
MO4hum (P31512); FMO5hum (P49326); Drosophila melanogaster: FMO1Dro (Q9W1E9);
p.  strain SK1 (JC7986); FMOTyr, Tyria jacobaeae (D6CHF7); FMOFish, Oncorhynchus mykiss
NP  251076); IucD Lys, Escherichia coli (YP 444061.1); SidA Orn, Aspergillus fumigatus (XP
I  FMOs A-G from R. jostii RHA1 described in this study].verexpression was  observed.
pression vector while all others have been expressed using the pBADN-vector [16].
from Type I BVMOs. Based on these observations, we  annotate
monooxygenase H as an NMO  (NMO-H). The other proteins seem
to form another isolated cluster of sequence-related class B ﬂavo-
protein monooxygenases and therefore we classify them as Type
II FMOs (while the known and well-established FMO  class can be
considered as Type I FMOs). Recently another class B ﬂavopro-
tein monooxygenase has been described that shows relatively high
sequence similarity with these Type II FMOs (FMO-X in Fig. 1). The
Grogan group has discovered this bacterial monooxygenase that
B ﬂavoprotein monooxygenases. The included sequences are: type I BVMOs  [EtaA,
Q93TJ5.1); CDMO, R. ruber SCI (AAL14233.1); CPDMO, Pseudomonas sp. strain HI-70
mobiﬁda fusca (YP 289549.1); STMO, R. rhodochrous (BAA24454.1); ACMO, Gordania
nas sp. strain NCIMB 9872 (Q8GAW0)], [BVMOs 1–23 from R. jostii RHA1 (see [13]
7); Homo sapiens: FMO1hum(Q01740); FMO2hum (Q99518); FMO3hum (P31513);
 FMO2Dro (Q7K3U4); FMO1dog, Canis familiaris (Q95LA2); FMOMeth, Methylophaga
 (B2LGF9)], NMOs [NRho Orn, R. jostii RHA1 (YP 704660.1); PVDA Orn, P. aeruginosa
 755103.1)], type II FMOs [FMO X, Stenotrophomonas maltophilia (B2FLR2); the type



































BScheme 1. Oxidations of thioanisole and phenylacetone catalyzed by th
an perform sulfoxidations and can act as BVMO [20]. However,
onversion rates described for this monooxygenase seem rather
odest (100–1000-fold lower when compared with conversion
ates of Type I BVMO).
This sequence analysis hints to a new subclass of class B ﬂavo-
rotein monooxygenases, Type II FMOs that can be employed as
iocatalysts. By cloning, expressing, and testing biocatalytic oxida-
ions, we set out to explore the above-mentioned 8 putative class
 ﬂavoprotein monooxygenases.
.2. Expression of the putative class B ﬂavoprotein
onooxygenases
The targeted genes were cloned in a pBAD-based expression
ector (pBADN, [17]) by ligation free cloning. By varying the
emperature and arabinose concentration, optimal expression con-
itions were determined. By this approach, 6 proteins could be
btained in soluble form with good expression levels (Table 1). Only
or 2 genes, expression did not yield satisfying amounts of soluble
rotein. We  solved this expression problem by cloning the respec-
ive genes into the recently developed pCRE2 expression vector
18]. With these constructs we were able to achieve soluble expres-
ion of all targeted proteins that were predicted to represent class
 ﬂavoprotein monooxygenases.
Interestingly, in two cases, FMO-E and FMO-G, it was  found that
uring expression the growth medium developed a bluish color.
e have previously observed this phenomenon when express-
ng a phenylacetone monooxygenase mutant capable of converting
ndole into indigo blue [21]. Also the expression of several type
 BVMOs from R. jostii RHA1 led to blue pigment formation [14].
he same phenomenon has been observed when expressing a
acterial FMO  in E. coli [22]. Apparently, the respective monooxy-
enases are able to form indigo blue by oxidizing the endogenous
ndole. The fact that indigo blue formation is only observed
pon expression of distinct enzymes, conﬁrms the functional
xpression of these monooxygenases, in our case of FMO-E and
MO-G.
able 2
aeyer–Villiger oxidation of phenylacetone and (±)-bicyclo[3.2.0]hept-2-en-6-one.
Phenylacetone conv. (%) (±)-Bicyclo[3.2.0]hept-2-e
Conv. (%) Ra
FMO-E 20 100 
FMO-F 19 88 
FMO-G 5 100 el ﬂavoprotein monooxygenases using NADH or NADPH as coenzymes.
3.3. Substrate proﬁle of the overexpressed monooxygenases
Even though using CCE for the reactivity tests, we  used the
same concentration of recombinant enzyme in all assays to allow
a direct comparison of the results. For this, the amount of active
enzyme in the CCEs was ﬁrst quantiﬁed with the NADPH-mediated
ﬂavin reduction method established and described before [14]. This
revealed that all extracts contained signiﬁcant amounts of NADPH-
dependent ﬂavoproteins, which is in agreement with the SDS-PAGE
analysis of CCEs, and conﬁrms that all enzymes contain a ﬂavin
cofactor upon expression and accept NADPH as coenzyme.
To determine the biocatalytic potential of the studied
monooxygenases, each monooxygenase was tested for activ-
ity on several ketones and aromatic sulﬁdes: 2-indanone,
cyclopentadecanone, phenylacetone, bicyclo[3.2.0]hept-2-en-6-
one, thioanisole, 4-methylthioanisole, ethyl benzyl sulﬁde, and
benzyl phenyl sulﬁde.
None of the monooxygenases was  found to convert 2-indanone
or cyclopentadecanone. In contrast, intriguingly, FMO-E, FMO-F,
and FMO-G were found to be able to convert phenylacetone and
bicyclo[3.2.0]hept-2-en-6-one (Scheme 1). Product analysis by GC
revealed that phenylacetone was  converted into the correspond-
ing ester, benzylacetate (Table 2). Enantiodivergent oxidation of
bicyclo[3.2.0]hept-2-en-6-one was  analyzed by chiral GC. This
revealed that the monooxygenases have a preference for the for-
mation of the normal lactone, while still a signiﬁcant amount of the
abnormal lactone is formed (Table 2). While the biocatalysts are not
very enantioselective in formation of the normal lactone, the FMO-
F and FMO-G yield >65% ee for the abnormal (1S,5R) enantiomer.
Taken together, these data show that FMO-E, FMOF and FMO-G act
as bona vide BVMOs.
Next, four prochiral aromatic sulﬁdes with varying substituents
(thioanisole, 4-methylthioanisole, ethyl benzyl sulﬁde, and ben-
zyl phenyl sulﬁde) were tested as substrates. The relatively smalln-6-one
tio normal:abnormal ee Normal (%) ee Abnormal (%)
79:21 9 (1S,5R) 7 (1R,5S)
78:22 <1 (1S,5R) 70 (1S,5R)
78:22 7 (1R,5S) 66 (1S,5R)
substrate thioanisole was the only sulﬁde that was converted
by most of the monooxygenases in detectable amounts, as indi-
cated in Table 3. Only NMO-H did not convert signiﬁcant amounts
of thioanisole or any other tested sulﬁde, strengthening the




Conv. (%) ee (%) Conﬁguration
FMO-A 5 11 R
FMO-B 4 7 R
FMO-C 4 33 R
FMO-D 16 25 R

















































sFMO-F 9 ≤5 –
FMO-G 21 57 S
lassiﬁcation of this particular enzyme as a NMO. For the majority
f the biocatalysts, mainly the (R)-methyl phenyl was  preferen-
ially formed, with the exception of FMO-G, which led to the
S)-enantiomer. The enantioselectivity of the thioanisole sulfoxi-
ation varied from low to moderate, achieving the highest optical
urity (ee = 57%), when employing FMO-G. The conversion of 4-
ethylthioanisole could only be detected in very low conversions.
his is in line with the observation of Grogan that FMO-X only
howed a poor conversion rate with this aromatic sulﬁde [20].
he enantioselective outcome with this substrate when using the
ype II FMOs from R. jostii RHA1 was similar to that achieved with
hioanisole. The more bulky substrate benzyl ethyl sulﬁde was only
onverted by FMO-E, FMO-F and FMO-G, but with poor conver-
ion. Only the corresponding methyl phenyl sulfone was detected
s product, indicating that these biocatalysts are able to oxygenate
he initially formed sulfoxide to the overoxidized product. The
ulky benzyl phenyl sulﬁde was not converted by any of the tested
onooxygenases.
FMO-X was found to be indifferent toward NADPH or NADH
20]. This is in sharp contrast with the known Type I BVMOs which
nly accept NADPH as coenzyme. It also is different from the Type
 FMOs, that typically prefer NADPH as a coenzyme. Conversion
f several of the previously identiﬁed substrates where therefore
ested via GC with both nicotinamide cofactors. When we  replaced
ADPH by NADH, almost identical degrees of conversion and enan-
ioselectivities were found for the conversions for all tested Type
I FMOs. This is a highly interesting and relevant ﬁnding as it sug-
ests that the Type II FMOs have as general characteristic a relaxed
oenzyme speciﬁcity. This is attractive for biocatalytic applications,
s NADH is a cheaper source than it phosphorylated analog (when
onsidering use as isolated enzyme) while NADH is also present
t higher level in cells (when considering use of whole cells). This
hows that the Type II FMOs described in this paper, together with
he previously described FMO-X [20], represent a newly discovered
ubclass of class B ﬂavoprotein monooxygenases that can accept
oth NADPH and NADH.
. Discussion
Eight class B ﬂavoprotein monooxygenases from R. jostii RHA1
ave been expressed in soluble form and studied for their bio-
atalytic potential. From the sequence alignment study, one of
he targeted monooxygenases (NMO-H) was found to belong to
he group of NMOs. The prototype enzymes for the subclass
f N-hydroxylating ﬂavoprotein monooxygenases (NMOs) are l-
rnithine N5-hydroxylase and l-lysine N6-hydroxylase [25]. An
-ornithine hydroxylase had already been identiﬁed in the R. jostii
HA1 proteome (Rmo Orn in Fig. 1, [26]). When comparing NMO-H
ith known NMO  sequences it shows highest sequence similarity
ith the lysine hydroxylase IucD from E. coli (Fig. 1). This sug-
ests that the NMO-H described in this study probably represents a
ysine hydroxylase present in R. jostii RHA1. The restricted substrate
cope of lysine hydroxylases also is in line with the observation thatlysis B: Enzymatic 88 (2013) 20– 25
NMO-H is not converting any aromatic compound tested in this
study [27]. This conﬁrms that, in contrast to BVMOs and FMOs,
NMOs are rather restricted in substrate acceptance and appear to
be of little value as biocatalysts.
The FMOs described in this paper do not seem to belong to
the typical FMO  subclass as (i) they do not contain a fully con-
served FMO-typifying motif (Table 1), and (ii) they form another
cluster of sequence-related proteins distinct from the three other
subclasses, FMOs, NMOs, and BVMOs (see Fig. 1). Also their cat-
alytic properties deviate from the other subclasses by accepting
both nicotinamide coenzymes, NADH and NADPH, without signif-
icant difference. Furthermore, several of these FMOs were shown
to perform Baeyer–Villiger oxidations, a reaction for which typical
FMOs display hardly any activity. We  coined this newly recog-
nized subclass of class B ﬂavoprotein monooxygenases Type II
FMOs.
This study reveals that of the tested Type II FMOs, FMO-E,
FMO-F, and FMO-G may  represent valuable new oxidative bio-
catalysts. These three enzymes were found to be active in both
sulfoxidations and Baeyer–Villiger reactions. Multiple sequence
alignment revealed that they form a separate cluster of sequences
(Fig. 1). Except for showing a relative high sequence homology
with each other, these three monooxygenases also share an N-
terminal extension of about 160 residues (see Fig. S1). This may
suggest that this newly identiﬁed subclass of monooxygenases has
evolved as separate subclass of class B ﬂavoprotein monooxyge-
nases, distinct from the Type I BVMOs, toward a new subclass
of potent Baeyer–Villiger monooxygenases. Therefore, these three
FMOs or close homologs thereof may  represent interesting alter-
native biocatalysts (for instance, due to their NADH acceptance)
when compared with the known Type I BVMOs. With merely using
the N-terminal sequence of one of three Type II FMOs, it is pos-
sible to identify hundreds of homologous putative Type II FMOs.
It will be exciting to see whether these homologs indeed display
similar biocatalytic properties. Future research will reveal whether
monooxygenases from this newly identiﬁed subclass of class B
ﬂavoprotein monooxygenases (Type II FMOs) are indeed valuable
as biocatalysts; e.g. their operational stability and substrate scope
has still to be explored.
5. Conclusions
In the present paper, a set of eight new ﬂavoprotein monooxy-
genases from R. jostii RHA1 has been expressed and obtained in
soluble form by employing two  expression vectors and optimizing
expression conditions. Sequence analysis established that one of
these enzymes represents a NMO, while the other cluster as a sep-
arate class B ﬂavoprotein monooxygenase subclass: Type II FMOs.
The monooxygenases have been tested for their ability to perform
sulfoxidations and Baeyer–Villiger oxidations. Interestingly, three
of the Type II FMOs are able to catalyze both reaction types and
accept both NADPH or NADH as coenzyme, presenting a different
behavior with respect to classical FMOs and BVMOs. Type II FMOs
might develop as an interesting alternative to BVMOs, as they are
able to catalyze the similar reaction with a relaxed nicotinamide
cofactor acceptance.
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